These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Lodde M; Lacombe L; Fradet Y Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155 [TBL] [Abstract][Full Text] [Related]
45. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer. Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455 [TBL] [Abstract][Full Text] [Related]
46. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. Wirth MP; See WA; McLeod DG; Iversen P; Morris T; Carroll K; J Urol; 2004 Nov; 172(5 Pt 1):1865-70. PubMed ID: 15540740 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. Siemens DR; Klotz L; Heidenreich A; Chowdhury S; Villers A; Baron B; van Os S; Hasabou N; Wang F; Lin P; Shore ND J Urol; 2018 Jan; 199(1):147-154. PubMed ID: 28827103 [TBL] [Abstract][Full Text] [Related]
48. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis. Cui Y; Zong H; Yan H; Li N; Zhang Y Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064 [TBL] [Abstract][Full Text] [Related]
50. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. Brawer MK BJU Int; 2003 Apr; 91(6):465-6. PubMed ID: 12656893 [No Abstract] [Full Text] [Related]
51. [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects]. Akaza H Gan To Kagaku Ryoho; 1999 Jul; 26(8):1201-7. PubMed ID: 10431591 [TBL] [Abstract][Full Text] [Related]
52. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763 [TBL] [Abstract][Full Text] [Related]
53. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. Ho TH; Nunez-Nateras R; Hou YX; Bryce AH; Northfelt DW; Dueck AC; Wong B; Stanton ML; Joseph RW; Castle EP Clin Genitourin Cancer; 2017 Apr; 15(2):196-202.e1. PubMed ID: 27771244 [TBL] [Abstract][Full Text] [Related]
54. [Monotherapy with antiandrogens for prostatic cancer]. Sander S Tidsskr Nor Laegeforen; 1999 Apr; 119(10):1451-3. PubMed ID: 10354754 [TBL] [Abstract][Full Text] [Related]
55. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T; J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [TBL] [Abstract][Full Text] [Related]
56. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Sciarra A; Cardi A; Di Silverio F Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347 [TBL] [Abstract][Full Text] [Related]
57. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373 [TBL] [Abstract][Full Text] [Related]
58. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells. Quéro L; Giocanti N; Hennequin C; Favaudon V Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473 [TBL] [Abstract][Full Text] [Related]
59. Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470 [TBL] [Abstract][Full Text] [Related]
60. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Beardsley EK; Hotte SJ; North S; Ellard SL; Winquist E; Kollmannsberger C; Mukherjee SD; Chi KN Invest New Drugs; 2012 Aug; 30(4):1652-9. PubMed ID: 21785998 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]